BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hillhouse E, Mathurin K, Bibeau J, Parison D, Rahal Y, Lachaine J, Beauchemin C. The Economic Impact of Originator-to-Biosimilar Non-medical Switching in the Real-World Setting: A Systematic Literature Review. Adv Ther 2022;39:455-87. [PMID: 34780028 DOI: 10.1007/s12325-021-01951-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Brownlee WJ, Wolf C, Hartung HP, Dingermann T, Anshasi N, Clark RA, Trojano M, Selmaj K, Uitdehaag BM, Tur C, Wuerfel J, Dallmann G, Witte J, Sintzel M, Bobrovnikova O, Cohen JA. Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations. Mult Scler 2022;:13524585221116269. [PMID: 36000489 DOI: 10.1177/13524585221116269] [Reference Citation Analysis]
2 Kulikov AY, Serpik VG, Lila AM. Pharmacoeconomic rationale for switching patients with rheumatic diseases from original biologic disease-modifying antirheumatic drugs to biosimilars in context of the Russian healthcare system. Sovremennaâ revmatologiâ 2022;16:1-17. [DOI: 10.14412/1996-7012-2022-2s-1-17] [Reference Citation Analysis]
3 Conran CA, Moreland LW. A review of biosimilars for rheumatoid arthritis. Curr Opin Pharmacol 2022;64:102234. [PMID: 35552095 DOI: 10.1016/j.coph.2022.102234] [Reference Citation Analysis]
4 Originator-to-biosimilar non-medical switch may not yield such great cost savings. PharmacoEcon Outcomes News 2021;892:17-17. [DOI: 10.1007/s40274-021-08212-z] [Reference Citation Analysis]